Bank of New York Mellon’s VanEck Pharmaceutical ETF PPH Stock Holding History

Bank of New York Mellon’s Portfolio PPH Stock Details PPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-5,100	Closed	-$268K	–	4315
2016 Q4	$268K	Buy	5,100 +100	+2%	+$5.34K	﹤0.01%	3815
2016 Q3	$287K	Hold	5,000	–	–	﹤0.01%	3777
2016 Q2	$293K	Sell	5,000 -6	-0.1%	-$350	﹤0.01%	3755
2016 Q1	$287K	Buy	5,006 +5	+0.1%	+$296	﹤0.01%	3660
2015 Q4	$327K	Sell	5,001 -65	-1%	-$4.2K	﹤0.01%	3689
2015 Q3	$319K	Sell	5,066 -1,734	-26%	-$122K	﹤0.01%	3746
2015 Q2	$481K	Sell	6,800 -1	-0%	-$72	﹤0.01%	3652
2015 Q1	$478K	Buy	6,801 +1	+0%	+$68	﹤0.01%	3627
2014 Q4	$437K	Hold	6,800	–	–	﹤0.01%	3669
2014 Q3	$432K	Hold	6,800	–	–	﹤0.01%	3686
2014 Q2	$422K	Sell	6,800 -1	-0%	-$59	﹤0.01%	3654
2014 Q1	$397K	Buy	6,801 +1,801	+36%	+$102K	﹤0.01%	3654
2013 Q4	$266K	Hold	5,000	–	–	﹤0.01%	3777
2013 Q3	$239K	Hold	5,000	–	–	﹤0.01%	3745
2013 Q2	$227K	Buy	+5,000	New	+$231K	﹤0.01%	3744

Other funds holding PPH

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

RJA

Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

SCM

Stuyvesant Capital Management Armonk, New York $41.1M AUM 17.11% 1-Year Est. Return

Colrain Capital Boston, Massachusetts $295M AUM 82.72% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Bank of New York Mellon's PPH Position: Q1 2017 in Review

Bank of New York Mellon sold out of VanEck Pharmaceutical ETF (PPH) in Q1 2017, closing a stake of 5,100 shares — an estimated $268K sold.

Bank of New York Mellon first reported a position in PPH in Q2 2013 and held it in 15 quarters. The position peaked at $481K in Q2 2015. 50 funds tracked by Wall St. Rank hold PPH as of Q1 2017.

Bank of New York Mellon reported no remaining VanEck Pharmaceutical ETF position as of Q1 2017 after selling out during the quarter.
Bank of New York Mellon sold 5,100 VanEck Pharmaceutical ETF shares in Q1 2017, an estimated $268K.
Bank of New York Mellon first reported a position in VanEck Pharmaceutical ETF in Q2 2013 and held it in 15 quarters.
Bank of New York Mellon's VanEck Pharmaceutical ETF position peaked at $481K in Q2 2015.
50 funds tracked by Wall St. Rank held VanEck Pharmaceutical ETF as of Q1 2017.

Based on Bank of New York Mellon's 13F filing for Q1 2017, filed 3 May 2017.